|
|
|
Volumn , Issue , 2010, Pages 383-390
|
|
Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALLOANTIBODY;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
HLA ANTIGEN;
IMMUNOLOGICAL ADJUVANT;
IMMUNOSUPPRESSIVE AGENT;
PROTEASOME;
PROTEINASE INHIBITOR;
PYRAZINE DERIVATIVE;
ACUTE DISEASE;
ADULT;
ARTICLE;
BLOOD;
CASE REPORT;
DRUG ANTAGONISM;
DRUG EFFECT;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMAN;
HUMORAL IMMUNITY;
IMMUNOLOGY;
KIDNEY TRANSPLANTATION;
MALE;
METABOLISM;
MIDDLE AGED;
SAUDI ARABIA;
TIME;
TREATMENT OUTCOME;
ACUTE DISEASE;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
BORONIC ACIDS;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HLA ANTIGENS;
HUMANS;
IMMUNITY, HUMORAL;
IMMUNOSUPPRESSIVE AGENTS;
ISOANTIBODIES;
KIDNEY TRANSPLANTATION;
MALE;
MIDDLE AGED;
PROTEASE INHIBITORS;
PROTEASOME ENDOPEPTIDASE COMPLEX;
PYRAZINES;
SAUDI ARABIA;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 79960037721
PISSN: 08909016
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
